{"schema_version":"secwatch.filing_event.v1","accession":"0000832101-23-000017","form_type":"8-K","ticker":"IEX","cik":"0000832101","company_name":"IDEX CORP /DE/","filed_at":"2023-04-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.387764+00:00","generated_at":"2026-06-16T10:25:08.642548+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"IDEX records Q1 sales record, cuts FY2023 adj. EPS guidance amid HST inventory correction; announces acquisition","bullets":["Record Q1 sales $845M (+13% YoY); reported EPS $1.84, adjusted EPS $2.09 (+7% vs $1.96).","Health & Science Technologies inventory correction larger than expected; full-year adjusted EPS guidance lowered to $8.25–$8.55.","Agreed to acquire Iridian Spectral Technologies for CAD$150M; expected to close Q2 2023.","Operating cash flow $148M (+86% YoY); free cash flow $121M (+91%).","FMT segment margin up 50bps to 33.0%, FSDP up 160bps to 28.5%, HST down 300bps to 28.7%."],"urls":{"canonical":"https://secwatch.observer/filing/0000832101-23-000017","json":"https://secwatch.observer/filing/0000832101-23-000017.json","markdown":"https://secwatch.observer/filing/0000832101-23-000017.md","text":"https://secwatch.observer/filing/0000832101-23-000017.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/832101/000083210123000017/0000832101-23-000017-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/832101/000083210123000017/iex-20230426.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T10:25:08.642548+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"01b07fa6e676f815b5d05ac1f757e029ffcb7a43","claim":"IDEX CORP /DE/ reported the three month period ended March 31, 2023 results: revenue $845.4 million, net income $139.8 million, EPS $1.84.","evidence_excerpt":"(847) 498-7070 IDEX REPORTS FIRST QUARTER RESULTS First Quarter 2023 Highlights (All comparisons against the first quarter of 2022 unless otherwise noted) • Record sales of $845 million, up 13% overall and 6% organically • Reported EPS of $1.84, up 1% and adjusted EPS of $2.09, up 7% • Strong operating cash flow of $148 million, up 86%; free cash flow of $121","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/832101/000083210123000017/0000832101-23-000017-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three month period ended March 31, 2023"},{"label":"Revenue","value":"$845.4 million"},{"label":"Net income","value":"$139.8 million"},{"label":"EPS","value":"$1.84"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"301d5be3ce8b434bf71a791e1dc5b0e19a96c607","claim":"IDEX CORP /DE/ reported full year 2023 results: EPS $8.25 to $8.55 per share. Guidance lowered.","evidence_excerpt":"Based on our current outlook, we are lowering our full year 2023 adjusted EPS guidance to $8.25 to $8.55 per share.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/832101/000083210123000017/0000832101-23-000017-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2023"},{"label":"EPS","value":"$8.25 to $8.55 per share"},{"label":"Guidance","value":"lowered"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}